Search Results 61-70 of 17391 for hba1c

1. Bone and joint problems associated with diabetes - Mayo Clinic

   Certain factors, such as nerve damage (diabetic neuropathy), arterial disease and obesity, may cause these problems — but often the cause isn't clear. Learn ...

2. Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis - Mayo Clinic

   HbA1c ≥ 9.5% within 90 days before Day 1. LDL cholesterol ≥ 190 mg/dL and already on a stable dose of LDL-lowering medication for ≥ 30 days. LDL ...

3. A Study to Evaluate the Effect of Hyperoxia on Glucose Metabolism in Type 2 Diabetics - Mayo Clinic

   HbA1c 6.5% -9.5%; FPG ≥126 mg/dL (7.0 mmol/L) <270 mg/dl at screening; 25 to 60 years of age; BMI 22-37 kg/m². Exclusion Criteria. Diabetic meds other than ...

4. Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) - Mayo Clinic

   Patients with decompensated diabetes (HbA1c>9%). Patients with a history of clinically significant acute cardiac event within 6 months prior to screening ...

5. Type 2 Diabetes Clinical Trials - Mayo Clinic Research

   The purpose of this study is to assess the effectiveness of Revita® DMR for improving HbA1c to ≤ 7% without the need of insulin in subjects with T2D ...

6. A Study to Evaluate the Effect of Improving Glycemic Control on Gastric Emptying in Type 1 and Type 2 Diabetes Mellitus - Mayo Clinic

   Participation eligibility · T1DM or T2DM of duration ≥ 5 years. · HbA1C > 7.5 %. · Able to provide written informed consent before participating in the study.

7. Insulin and weight gain: Keep the pounds off - Mayo Clinic

   Understand why weight gain is linked to insulin treatment, and find out how to dodge those extra pounds while still managing your blood sugar.

8. INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes - Mayo Clinic

   Participation eligibility · Same treatment regimen (MDI, an AID system, or an insulin pump without automation) for the 3 months prior to screening: · HbA1c < 11.0 ...

9. Dual-Hormone Control of Post-absorptive and Post-prandial Glucose in Type 1 Diabetes - Mayo Clinic

   HbA1c ≤ 10%; On insulin pump therapy for at least six months; no symptomatic gastroparesis; no unstable retinopathy (requiring photocoagulation within past 6 ...

10. Shared Savings Program Public Reporting - Mayo Clinic

    *For Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) [Quality ID #001], Hospital-Wide, 30-Day,. All-Cause Unplanned Readmission (HWR) Rate for MIPS ...